Akeso, Inc. (9926.HK), established in 2012, is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide.

Since our establishment, the Company has established a comprehensive in-house drug development platform (ACE Platform), encompassing fully integrated drug discovery and development functions, including target validation, antibody drug discovery and development, process development, and GMP-compliant commercial-scale manufacturing. The Company has also successfully established a bi-specific antibody drug development technology platform (Tetrabody Technology Platform).


The Company currently has a pipeline of over 30 innovative investigative drugs for the treatment of major diseases like cancer and autoimmune diseases, 16 ( including 3 out-licensed) of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The Company’s vision is to become a global leading biopharmaceutical company through the research and development of breakthrough new drugs that are first-in-class and best-in-class therapies.

In oncology therapeutic area, the products in advanced development include an anti-PD-1/CTLA-4 bi-specific antibody (AK104), an anti-PD-1 antibody (penpulimab (AK105) , and AK112, a potential first-in-class PD-1/VEGF bi-specific antibody.


In immunology therapeutic area, the Company has built one of the richest pipeline targeting autoimmune diseases among China-based biotech companies. Our product candidates in this area include anti-IL12/IL23 monospecific antibody (AK101), an anti-IL17 monospecific antibody (AK111), one drug candidate Complete patient enrollment for phase II study (AK120, an IL-4R antibody), and one more in IND-enabling stage (AK114, an IL-1 beta antibody).